Doripenem monohydrate, a broad-spectrum carbapenem antibiotic

Matthews, S. James; Lancaster, Jason W.

doi:10.1016/j.clinthera.2009.01.013

Cited by 51 publications

(51 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It shows antibacterial activity against a broad range of Gram-positive and Gram-negative bacteria, as well as a variety of anaerobes, [1][2][3] joining imipenem, meropenem and ertapenem. 4,5 The drug is marketed as a crystalline powder for reconstitution and injection, and differently from other carbapenems there is no excipient in the formulation.…”

Section: Introductionmentioning

confidence: 99%

Characterization of the antibiotic doripenem using physicochemical methods: chromatography, spectrophotometry, spectroscopy and thermal analysis

et al. 2011

View full text Add to dashboard Cite

Recebido em 1/11/10; aceito em 14/5/11; publicado na web em 22/7/11 Doripenem was characterized through physicochemical and spectroscopic techniques, as well as thermal analysis. TLC (Rf = 0.62) and HPLC (rt = 7.4 min) were found to be adequate to identify the drug. UV and infrared spectra showed similar profile between doripenem bulk and standard. The 1 H and 13 C NMR analysis revealed chemical shifts that allowed identifying the drug. Thermal analysis demonstrated three steps with mass loss, at 128, 178 and 276 o C. The work was successfully applied to qualitative analysis of doripenem, showing the reported methods can be used for physicochemical characterization of doripenem.

show abstract

Section: Introductionmentioning

confidence: 99%

Characterization of the antibiotic doripenem using physicochemical methods: chromatography, spectrophotometry, spectroscopy and thermal analysis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Son yıllarda farklı antimikrobiyal aktiviteye sahip çok sayıda karbapenem geliştirilmiştir [9,10]. Yeni bir karbapenem olan doripenem, komplike intraabdominal ve idrar yolu enfeksiyonları ile nozokomiyal pnömoni ve ventilatörle iliş-kili pnömoni tedavisinde etkili bir ajandır [12][13][14][15]. Ayrıca, imipeneme göre santral sinir sistemi yan etkilerinin daha düşük olması ve uzun süreli infüzyon ile yüksek serum konsantrasyonlarına ulaşabilmesi nedeniyle hastane kaynaklı komplike bakteriyel enfeksiyonların tedavisinde ümit veren bir antibiyotiktir [15].…”

Section: Discussionunclassified

Comparison of Disk Diffusion and E-Test Methods for Doripenem Susceptibility of Nosocomial Acinetobacter Baumannii Strains

Çekın¹,

Güvenç²,

Baysan³

et al. 2015

Ann Clin Anal Med

View full text Add to dashboard Cite

ÖzetAmaç: Acinetobacter türleri son yıllarda hastanemiz yoğun bakım hastaların-da en sık rastlanan ilk iki etken arasında yer almaktadır. Ülkemizde kullanıma yeni sunulan doripenem, bakteri hücre duvarı sentezini inhibe ederek etkinlik gösteren, karbapenem grubu geniş spektrumlu bir antibiyotiktir. Çalışmalar-da özellikle ventilatör ilişkili pnömoni etkeni olarak izole edilen Acinetobacter baumannii suşlarında doripenemin duyarlılıkları araştırılmıştır. Çalışmamız-da nozokomiyal infeksiyonlarda etken olarak izole edilen Acinetobacter baumannii suşlarının doripenem duyarlılıklarının saptanmasında disk diffüzyon ve E-test yöntemlerinin karşılaştırmayı amaçladık. Gereç ve Yöntem: Akdeniz Üniversitesi Merkez Laboratuvarı'na 1 Ocak-31 Aralık 2009 tarihleri arasında yoğun bakımlardan gelen çeşitli klinik örneklerden izole edilen toplam 94 Acinetobacter baumannii suşunun disk diffüzyon ve Etest yöntemleri ile doripenem duyarlılıkları belirlenmiştir. European Committee on Antimicrobial Susceptibility Testing (EUCAST) tarafından belirlenen minimal inhibitör konsantrasyonları (MİK); duyarlı ≤1 μg/ml, orta duyarlı 2-4 μg/ml ve dirençli >4 μg/ml olarak ve 10 μg'lık disklerle inhibisyon zonu çapları, duyarlı <15mm, direnç-li ≥21mm olarak kullanılmıştır. Bulgular: Disk diffüzyon yöntemiyle; 10 izolat duyarlı, 17 izolat orta duyarlı, 67 izolat ise dirençli saptanırken, E-test yönte-miyle; 12 izolat duyarlı, 12 izolat orta duyarlı, 70 izolat ise dirençli saptanmış-tır. E-test yöntemi ile disk diffüzyon yöntemi arasındaki kategorik uyum (orta duyarlı izolatlar dirençli kabul edilerek), %88.3 (83/94) olarak hesaplanmış-tır. Çalışmamızda büyük hata, ve küçük hata oranları sırasıyla %1.2 (1/82) ve %18.1 (17/94) olarak saptanmış, çok büyük hata saptanmamıştır. Tartışma: Sonuç olarak rutin laboratuvar pratiğinde Acinetobacter türlerine karşı doripenem duyarlılıkları saptanırken disk diffüzyon ile E-test yöntemlerinin yük-sek düzeyde uyum gösterdiği tespit edilmiştir. Anahtar KelimelerAcinetobacter Baumannii; E-Test; Disk Diffüzyon; Doripenem Abstract Aim: Acinetobacter species are amoung the most common two cause of infections isolated from patients of intensive care unit in our hospital. Doripenem which acts by inhibiting cell wall synthesis is resently introduced for use in our country is broad spectrum antibiotic belonging to carbapenems. There are many studies investigating the susceptibility of doripenem of Acinetobacter baumannii which is isolated as a cause of ventilatory associated pneumonia in the literature. We aimed to compare e-test and disc diffusion methods for doripenem susceptibility of acinetobacter baumannii strains as nosocomial infections Acinetobacter baumanni isolates detected as nosocomial infection. Material and Method:. Between January to December, 2009 a total of 94 Acinetobacter baumanni strains isolated from different clinical specimens from intensive care units have been studied for doripenem susceptibility by disc diffusion and E-test methods. Minimal inhibitory consantrations (MIC) were accepted as; sen...

show abstract

“…Use for NP is currently being evaluated in the US. 2,4,[6][7][8][9] It is marketed in these countries under the names DORIBAX ® , DORIPREX ® , and DURAPTA ® . It is also marketed under the name FINIBAX ® in Japan.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…[1][2][3][4][5][6][7][8][9][10][11][12] It demonstrates potent activity against Gram-negative and Gram-positive aerobic and anaerobic organisms. [1][2][3][4][6][7][8]10,11,13 Doripenem is currently indicated in the United States (US) for treatment of adults with complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI), including pyelonephritis, by 1-hour intravenous (IV) infusion. [2][3][4][5][6][7]9,10,14 In the European Union and other countries in Europe, the Americas, and Asia Pacific, doripenem carries these indications, in addition to an indication for nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP), with infusion times of 1 hour or 4 hours.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Review of Doripenem for the Treatment of Serious Bacterial Infections

Redman

Flamm²,

Cirillo³

2010

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

Doripenem is a carbapenem bactericidal agent that demonstrates in vitro activity against a wide variety of Gram-negative and Gram-positive pathogens. In vitro data show that doripenem combines the intrinsic activity of meropenem against Gram-negative pathogens with the intrinsic activity of imipenem against Gram-positive pathogens. The availability of doripenem is particularly welcome in the current setting of increased resistance among Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter species, and extended-spectrum β-lactamase-producing Enterobacteriaceae. Characteristic of doripenem is its potent activity against P. aeruginosa with a minimum inhibitory concentration (MIC) necessary for the inhibition of 90% of all isolates (MIC 90 ) of 4 µg/mL, a value that is 2 to 4 times lower than the corresponding MIC 90 values of meropenem and imipenem. Doripenem was shown to be noninferior to other commonly used antibiotics in phase 3 clinical trials and is currently approved for the treatment of complicated intra-abdominal infection and complicated urinary tract infection, and in some countries for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia. Intravenous (IV) infusions of doripenem can be either 1 hour or for longer durations of 4 hours. Overall, IV doripenem is safe and well tolerated, with a limited propensity to induce seizures compared with other carbapenems. Doripenem may represent a valuable option when carbapenem therapy is warranted for the treatment of serious infection, particularly in cases in which the etiology is a drug-resistant, Gram-negative pathogen.

show abstract

Doripenem monohydrate, a broad-spectrum carbapenem antibiotic

Cited by 51 publications

References 74 publications

Characterization of the antibiotic doripenem using physicochemical methods: chromatography, spectrophotometry, spectroscopy and thermal analysis

Characterization of the antibiotic doripenem using physicochemical methods: chromatography, spectrophotometry, spectroscopy and thermal analysis

Comparison of Disk Diffusion and E-Test Methods for Doripenem Susceptibility of Nosocomial Acinetobacter Baumannii Strains

A Review of Doripenem for the Treatment of Serious Bacterial Infections

Contact Info

Product

Resources

About